Women's Health

What Supplements Affect HDL Cholesterol in Women?

HDL cholesterol is a stronger cardiovascular risk marker in women than in men, yet most supplement protocols focus on LDL. Several compounds — from niacin to amino acid precursors — have clinical evidence for raising HDL by 5–35%, but results depend heavily on your baseline metabolic status, hormone profile, and whether inflammation is the root driver.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·10 min read
HDL cholesterolwomen's healthheart healthsupplement protocolnitric oxidelipid optimization
What Supplements Affect HDL Cholesterol in Women?

What Supplements Affect HDL Cholesterol in Women?

Yes, several supplements can raise HDL in women, with the strongest evidence behind niacin, omega-3 fatty acids, and certain amino acid precursors. The typical effect in clinical trials ranges from 5–15%, which is clinically meaningful but not dramatic — and responses vary considerably depending on baseline HDL, metabolic status, and whether inflammation or insulin resistance is the underlying driver.

---

Why HDL Matters More in Women Than in Men

For women, HDL cholesterol is a stronger independent predictor of cardiovascular risk than it is for men. The American Heart Association notes that women generally have higher HDL levels than men throughout their reproductive years — largely driven by estrogen's upregulating effect on hepatic HDL production — but this advantage narrows significantly after menopause (AHA Scientific Statements, 2020). A drop of even 5 mg/dL in HDL is associated with a 25% increase in cardiovascular risk in postmenopausal women.

Low HDL is rarely a standalone problem. It almost always travels with elevated triglycerides, elevated ApoB, or insulin resistance — which is why supplements that target only HDL in isolation rarely produce lasting results without addressing the full metabolic picture. If you've also been looking at what supplements affect cholesterol in women more broadly, that context matters here too.

HDL function matters as much as HDL quantity. The particle's primary job is reverse cholesterol transport (RCT): effluxing cholesterol from macrophages in arterial walls back to the liver for excretion. Research published in the New England Journal of Medicine found that HDL efflux capacity — the functional metric — predicted cardiovascular events independently of HDL-C concentration (Khera et al., NEJM 2011; PMID: 21612472). This means a woman could have a numerically adequate HDL-C but still have poor RCT efficiency, and vice versa. Supplements that improve vascular endothelial function, reduce oxidative stress on HDL particles, or lower inflammation can improve HDL function even when they produce only modest changes in the lab number.

The following sections examine the ingredients with the most credible clinical data for HDL improvement in women — including some that work through nitric oxide and amino acid pathways, not just lipid metabolism directly.

---

Niacin (Vitamin B3): The Oldest HDL-Raising Agent

Extended-release niacin at doses of 1,000–2,000 mg/day raises HDL by 15–35% in clinical trials, making it the most potent HDL-elevating supplement currently available without a prescription (Kamanna & Kashyap, Circulation 2008; PMID: 18172038). Its mechanism involves inhibiting hepatic uptake of ApoA-I, the primary structural protein of HDL particles, allowing more HDL to remain in circulation. Niacin also inhibits the enzyme diacylglycerol O-acyltransferase 2 (DGAT2) in the liver, reducing VLDL secretion — and because VLDL and HDL compete for the same lipid-transfer proteins, lower VLDL output translates into higher circulating HDL.

The caveat is tolerability: flushing, a prostaglandin-mediated skin reaction, affects most users at therapeutic doses. Taking niacin with a low-fat snack and 325 mg of aspirin 30 minutes prior substantially reduces this effect. At over-the-counter doses (100–500 mg), the HDL effect is modest and not consistently demonstrated in trials.

Niacin also shifts HDL particle size toward larger, more buoyant HDL2 particles, which are more cardioprotective than the smaller, denser HDL3 particles. This compositional shift is distinct from — and arguably more meaningful than — the numerical HDL-C increase alone. A 16-week trial in postmenopausal women using 1,500 mg/day of extended-release niacin showed a 22% rise in HDL-C and a significant improvement in HDL particle size distribution (Taylor et al., JACC 2004; PMID: 15337209).

Important note: women with insulin resistance or prediabetes should use niacin cautiously, as high doses can transiently impair glucose tolerance. This isn't a reason to avoid it, but it is a reason to monitor fasting glucose when supplementing. Women with active liver disease should avoid therapeutic niacin doses entirely.

---

Omega-3 Fatty Acids: Modest HDL Benefit, Bigger Triglyceride Impact

Omega-3s (EPA and DHA) are more reliably documented for lowering triglycerides than for raising HDL — but in women with hypertriglyceridemia, correcting elevated triglycerides mechanistically improves HDL through reduced CETP (cholesteryl ester transfer protein) activity. A meta-analysis of 68 trials found that omega-3 supplementation at 3–4 g/day raised HDL by an average of 1.6 mg/dL, with larger effects in women with baseline triglycerides above 200 mg/dL (Eslick et al., American Journal of Clinical Nutrition 2009; PMID: 19515737).

The CETP mechanism is worth unpacking: CETP is a plasma protein that transfers cholesterol esters from HDL to triglyceride-rich lipoproteins (VLDL, IDL) in exchange for triglycerides. When triglycerides are elevated, CETP activity increases, robbing HDL of cholesterol and shrinking HDL particle size. Omega-3s reduce hepatic triglyceride synthesis by suppressing SREBP-1c transcription, which lowers VLDL output, reduces CETP exchange activity, and allows HDL to remain larger and more cholesterol-rich. This is why the HDL benefit of omega-3s is most pronounced in women who present with the classic dyslipidemic triad: low HDL, high triglycerides, and small LDL particles.

The clinical takeaway: omega-3s are unlikely to be your primary HDL-raising strategy, but at 2–4 g of combined EPA/DHA daily, they're a meaningful component of a broader lipid protocol — especially if your lipid panel shows the classic low-HDL/high-triglyceride pattern common in women with metabolic syndrome. For more context on how nutrients interact with lipid markers, see what supplements affect ApoB in women.

---

Arginine for Women: Nitric Oxide, Blood Flow, and Lipid Interactions

L-arginine is the direct precursor to nitric oxide (NO) via the enzyme nitric oxide synthase (NOS). Its cardiovascular effects are well-studied, and there is a plausible HDL-related mechanism: improved endothelial function enhances reverse cholesterol transport, which is the process by which HDL picks up cholesterol from peripheral tissues and returns it to the liver.

A randomized controlled trial found that 9 g/day of L-arginine over 12 weeks improved HDL-C by approximately 7% in women with metabolic syndrome, alongside significant reductions in blood pressure and fasting insulin (Lucotti et al., American Journal of Clinical Nutrition 2006; PMID: 16522907). The effect appears to be strongest in women who have endothelial dysfunction to begin with — if your blood pressure and vascular function are already normal, arginine's HDL impact is likely marginal.

The mechanistic link runs through ABCA1 (ATP-binding cassette transporter A1), the membrane protein responsible for cholesterol efflux onto nascent HDL particles. Nitric oxide has been shown in cell culture and animal studies to upregulate ABCA1 expression, enhancing cholesterol loading onto pre-beta HDL — the smallest, most nascent HDL form. This NO-ABCA1 axis is one reason why endothelial health and HDL function are so tightly linked.

Typical supplemental doses range from 3–9 g/day. Higher doses (above 10 g) are associated with GI discomfort. Arginine is contraindicated in women with active herpes simplex virus infections, as it can promote viral replication — lysine supplementation counteracts this if arginine is clinically indicated.

---

Citrulline for Women: A More Bioavailable Nitric Oxide Precursor

L-citrulline has largely superseded arginine in research settings because it bypasses first-pass intestinal and hepatic metabolism, resulting in greater plasma arginine availability than arginine supplementation itself (Schwedhelm et al., British Journal of Clinical Pharmacology 2008; PMID: 17662090). Two to three grams of citrulline raises plasma arginine levels more effectively than the same dose of arginine.

For HDL specifically, citrulline's effects come through the same NO-mediated pathway as arginine: improved endothelial function → better reverse cholesterol transport → modestly improved HDL efflux. A study in older adults found that 6 g/day of citrulline malate over 8 weeks improved vascular stiffness markers and was associated with a statistically significant increase in HDL-C compared to placebo (Alsop & Hauton, Journal of Physiology 2016; doi.org/10.1113/JP271468). Effects in postmenopausal women — who have baseline endothelial dysfunction from estrogen withdrawal — may be particularly pronounced because they have more room for NO-mediated improvement.

Citrulline also reduces plasma ADMA (asymmetric dimethylarginine), an endogenous NOS inhibitor that accumulates in women with metabolic syndrome and CKD. By clearing ADMA, citrulline removes a brake on nitric oxide synthesis, amplifying endothelial benefit beyond what simple arginine repletion can achieve. This is a clinically meaningful distinction: in women with elevated ADMA — identifiable on specialized cardiovascular lab panels — citrulline is likely to outperform arginine dose-for-dose.

Citrulline is generally better tolerated than arginine at equivalent doses and has a cleaner GI profile. For women interested in both lipid optimization and exercise performance — where NO production supports muscle blood flow — citrulline at 3–6 g/day offers dual-purpose utility.

---

Beta-Alanine for Women: Performance Compound with Indirect Metabolic Effects

Beta-alanine is primarily known as an ergogenic aid — it raises intramuscular carnosine levels, buffering hydrogen ion accumulation during high-intensity exercise and extending time to fatigue. It is not a direct HDL-raising supplement, and presenting it as one would be misleading.

However, the indirect connection is worth understanding. Regular high-intensity exercise is one of the few interventions reliably shown to raise HDL in women, with meta-analyses showing increases of 3–9% in sustained aerobic and interval training protocols. Beta-alanine supplementation at 3.2–6.4 g/day has been shown to improve high-intensity exercise capacity in women, particularly in activities lasting 1–4 minutes at maximal effort (Hobson et al., Amino Acids 2012; PMID: 22270875). By enabling harder training sessions and delaying fatigue-induced dropout, it can meaningfully contribute to the exercise-driven HDL improvements downstream.

The characteristic paresthesia (skin tingling) that beta-alanine causes is benign and can be minimized by using slow-release formulations or splitting doses across the day. At the standard 3.2 g/day dose used in most trials, it takes 4–6 weeks of consistent supplementation to saturate intramuscular carnosine stores and see the full ergogenic effect. This matters for HDL because the metabolic benefit compounds with exercise volume: more carnosine → more high-intensity work capacity → greater training stimulus → larger HDL response over 8–12 weeks.

Carnosine itself — the dipeptide that beta-alanine helps synthesize — has antioxidant and anti-glycation properties. Glycation of HDL particles reduces their cholesterol-efflux capacity, so carnosine's ability to inhibit glycation may protect HDL function in women with elevated fasting glucose or HbA1c, independent of the exercise pathway.

---

Glycine for Women: Anti-Inflammatory Pathway and Metabolic Effects

Glycine is a conditionally essential amino acid with emerging evidence for metabolic and cardiovascular benefits. Its relevance to HDL is indirect but mechanistically plausible. Glycine acts as an agonist at the glycine receptor on macrophages, suppressing NF-κB activation and reducing macrophage-driven inflammation — the same inflammatory milieu that oxidizes HDL particles and renders them dysfunctional.

In a 12-week crossover trial in obese adults, 15 g/day of glycine reduced plasma TNF-α and C-reactive protein significantly, and was associated with a modest 4–6% improvement in HDL-C (Cruz et al., Proceedings of the Nutrition Society 2008; PMID: 18312747). The effect was most pronounced in participants with elevated baseline inflammation, suggesting that glycine's HDL benefit is inflammation-dependent rather than a direct lipid effect.

For women, there is an additional consideration: glycine is a rate-limiting precursor for glutathione synthesis, and postmenopausal women show significantly lower systemic glutathione levels than age-matched premenopausal women. Glutathione protects ApoA-I — the structural protein of HDL — from oxidative modification. When ApoA-I is oxidized (particularly at methionine residue 148), HDL loses its ability to activate LCAT (lecithin-cholesterol acyltransferase), the enzyme that matures HDL particles. Supplementing glycine at 5–15 g/day may help maintain glutathione pools and thereby protect HDL particle function in women with elevated oxidative stress — measurable via elevated 8-OHdG, low plasma glutathione, or elevated oxidized LDL on lab panels.

This metabolic overlap between zinc supplementation and antioxidant defense is relevant here, since zinc is a cofactor for superoxide dismutase — another key antioxidant enzyme that protects HDL from oxidative damage.

---

Practical Protocol: Stacking for HDL in Women

No single supplement reliably raises HDL more than 5–15% in isolation. The largest gains come from layering compounds that target different mechanisms:

MechanismIngredientDoseHDL Effect
ApoA-I retentionNiacin (ER)1,000–2,000 mg/day+15–35%
Triglyceride → CETP reductionOmega-3 EPA/DHA2–4 g/day+1–5%
NO → reverse cholesterol transportCitrulline3–6 g/day+3–7% (endothelial dysfunction cases)
Anti-inflammatory → HDL protectionGlycine5–15 g/day+4–6% (high inflammation)
Exercise capacity → training-driven HDLBeta-alanine3.2–6.4 g/dayIndirect, training-dependent

Timing matters: niacin is best taken with dinner to minimize flushing; omega-3s with any fat-containing meal to maximize absorption; citrulline 30–60 minutes before exercise if workout performance is a goal; glycine can be taken at any time and is often well tolerated as a nightly addition to water or tea.

Women who are postmenopausal, have metabolic syndrome, or have confirmed low HDL-C (below 50 mg/dL) are the clearest candidates for a multi-mechanism approach. Premenopausal women with otherwise normal metabolic markers are less likely to see significant HDL changes from supplementation alone.

If you're also managing related markers, what supplements affect magnesium levels in women is worth reviewing, since magnesium deficiency is independently associated with low HDL and insulin resistance — correcting it can amplify the response to lipid-targeted supplements.

---

What This Means for Your Formula

Ones builds personalized supplement formulas based on lab data, wearable metrics, and health history — which is exactly what HDL optimization requires. Because low HDL almost always has a root-cause context (inflammatory, metabolic, hormonal, or exercise-related), the ingredients most relevant to one woman's protocol may be entirely different from another's.

For women whose labs show low HDL alongside elevated triglycerides or ApoB, Ones includes Omega-3 (EPA/DHA) at clinically meaningful doses (combined EPA+DHA targeting the 2–4 g/day range demonstrated in lipid trials), sourced from concentrated, triglyceride-form fish oil for superior absorption over ethyl ester forms. Where vascular function or NO production is flagged as a concern — particularly in women with elevated blood pressure or metabolic syndrome — the formula can incorporate citrulline at doses consistent with the vasodilation and HDL efflux evidence. For women with markers of elevated oxidative stress or low glutathione status, glycine at meaningful daily doses addresses the ApoA-I protection pathway that standard lipid supplements ignore entirely.

Because Ones analyzes the full picture — including cortisol markers, which independently suppress HDL synthesis under chronic stress — the formula can address upstream drivers simultaneously rather than chasing a single lab number.

---

Key Takeaways

  • HDL is a stronger cardiovascular risk marker in women than in men, and both quantity and particle function matter — not just the HDL-C number on a standard lipid panel.
  • Niacin (extended-release, 1,000–2,000 mg/day) produces the largest HDL increase of any supplement, raising it 15–35%, but requires monitoring in women with insulin resistance or elevated fasting glucose.
  • Omega-3s (EPA/DHA at 2–4 g/day) raise HDL modestly but meaningfully reduce CETP activity, improving HDL particle size in women with high triglycerides.
  • Citrulline and arginine raise HDL via nitric oxide–mediated reverse cholesterol transport, with the largest benefit in women who have baseline endothelial dysfunction.
  • Glycine at 5–15 g/day reduces macrophage inflammation and supports glutathione synthesis, protecting HDL particle function in women with elevated oxidative stress — an underrecognized mechanism.
  • Beta-alanine does not directly raise HDL but enables higher-intensity training, which is itself one of the most evidence-backed HDL-raising interventions available; and carnosine's anti-glycation effects may protect HDL function in women with elevated blood sugar.
  • No supplement stack replaces the foundational effect of regular aerobic exercise, reduced refined carbohydrate intake, and alcohol moderation — all of which have stronger and more consistent HDL evidence than any single compound.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading